Clinical Trial Update: An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating decitabine with talacotuzumab versus decitabine alone in adults with acute myeloid leukemia ineligible for intensive chemotherapy; tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Dacogen (decitabine) (decitabine)
• Talacotuzumab (JNJ-56022473) (talacotuzumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Leukemia, Myeloid, Acute | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2019-02-28